CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 218,057 Shares

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 218,057 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $15.89, for a total value of $3,464,925.73. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Kurt Von Emster also recently made the following trade(s):

  • On Thursday, July 19th, Kurt Von Emster acquired 153,846 shares of CymaBay Therapeutics stock. The shares were purchased at an average price of $6.50 per share, for a total transaction of $999,999.00.
  • On Wednesday, February 7th, Kurt Von Emster sold 40,763 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.35, for a total value of $503,423.05.
  • On Monday, February 5th, Kurt Von Emster sold 18,831 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.14, for a total value of $228,608.34.
  • On Friday, February 2nd, Kurt Von Emster sold 90,098 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.15, for a total value of $1,094,690.70.
  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.22, for a total value of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.18, for a total value of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.40, for a total value of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.25, for a total value of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.21, for a total value of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.41, for a total value of $1,629,736.72.

CymaBay Therapeutics Inc (NASDAQ:CBAY) opened at $14.98 on Friday. CymaBay Therapeutics Inc has a one year low of $2.56 and a one year high of $15.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. The firm has a market capitalization of $824.49, a price-to-earnings ratio of -14.69 and a beta of 2.36.

A number of hedge funds have recently made changes to their positions in CBAY. Perceptive Advisors LLC purchased a new position in CymaBay Therapeutics during the 3rd quarter worth $18,948,000. Farallon Capital Management LLC purchased a new position in CymaBay Therapeutics during the 4th quarter worth $10,120,000. Citadel Advisors LLC purchased a new position in CymaBay Therapeutics during the 3rd quarter worth $5,159,000. EAM Investors LLC acquired a new stake in CymaBay Therapeutics during the 3rd quarter worth about $4,788,000. Finally, UBS Asset Management Americas Inc. acquired a new stake in CymaBay Therapeutics during the 4th quarter worth about $5,423,000. Hedge funds and other institutional investors own 54.80% of the company’s stock.

Several research firms have commented on CBAY. ValuEngine upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Leerink Swann restated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Roth Capital reiterated a “buy” rating and issued a $27.00 price target on shares of CymaBay Therapeutics in a report on Thursday, January 25th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Finally, Evercore ISI assumed coverage on CymaBay Therapeutics in a report on Tuesday, February 13th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. CymaBay Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.56.

WARNING: “CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 218,057 Shares” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2018/02/18/cymabay-therapeutics-inc-cbay-director-kurt-von-emster-sells-218057-shares.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply